Determination of carbamazepine in pharmaceutical formulations

Detalhes bibliográficos
Autor(a) principal: Araujo, Aurigena Antunes de
Data de Publicação: 2010
Outros Autores: Solon, Lílian Grace da Silva, Oliveira, Ana Isabel Maia de, Guerra, Gerlane Coelho Bernardo, Soares, Luiz Alberto Lira
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Institucional da UFRN
Texto Completo: https://repositorio.ufrn.br/jspui/handle/123456789/25361
http://dx.doi.org/10.1590/S1984-82502010000300014
Resumo: The aim of this study was to evaluate the quality of five different solid formulations of carbamazepine. The reference formulation was Tegretol® 200.00 mg (Novartis) and the others were: generic formulation of carbamazepine 200.00 mg (National Industry), similar formulation of carbamazepine 200.00 mg (National Industry), and two formulations of carbamazepine 200.00 mg acquired from two different compounding pharmacies. The latter consisted of capsules obtained in Natal, the capital city of the Brazilian State of Rio Grande do Norte. The quality of samples was evaluated through physical and physical-chemical tests, including: weight, diameter, thickness, content, dissolution, disintegration, hardness, friability and moisture. The results of friability analysis showed that all formulations met Brazilian and United States Pharmacopeia (USP) specifications. In spite of having a higher hardness compared to the reference, the generic formulation had a lower disintegration time. This could be associated to the presence of crospovidone in its formulation. Results of this study showed that all formulations had dissolutions which were in accordance with Brazilian Pharmacopoeia specifications, and quality control tests. An exception was found for the similar formulation, which had a hardness parameter that exceeded the USP standard. However, this difference was not significant given the similar formulation's satisfactory disintegration time.
id UFRN_2001dc2d4a5ffd0bc0a1e3c633079d07
oai_identifier_str oai:https://repositorio.ufrn.br:123456789/25361
network_acronym_str UFRN
network_name_str Repositório Institucional da UFRN
repository_id_str
spelling Araujo, Aurigena Antunes deSolon, Lílian Grace da SilvaOliveira, Ana Isabel Maia deGuerra, Gerlane Coelho BernardoSoares, Luiz Alberto Lira2018-06-12T15:15:28Z2018-06-12T15:15:28Z2010ARAUJO, Aurigena Antunes de; et al. Determination of carbamazepine in pharmaceutical formulations. Brazilian Journal of Pharmaceutical Sciences (Impresso), v. 46, p. 509-513, 2010. Disponível em: < http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502010000300014> Acesso em: 13 mar. 2018.2175-9790https://repositorio.ufrn.br/jspui/handle/123456789/25361http://dx.doi.org/10.1590/S1984-82502010000300014The aim of this study was to evaluate the quality of five different solid formulations of carbamazepine. The reference formulation was Tegretol® 200.00 mg (Novartis) and the others were: generic formulation of carbamazepine 200.00 mg (National Industry), similar formulation of carbamazepine 200.00 mg (National Industry), and two formulations of carbamazepine 200.00 mg acquired from two different compounding pharmacies. The latter consisted of capsules obtained in Natal, the capital city of the Brazilian State of Rio Grande do Norte. The quality of samples was evaluated through physical and physical-chemical tests, including: weight, diameter, thickness, content, dissolution, disintegration, hardness, friability and moisture. The results of friability analysis showed that all formulations met Brazilian and United States Pharmacopeia (USP) specifications. In spite of having a higher hardness compared to the reference, the generic formulation had a lower disintegration time. This could be associated to the presence of crospovidone in its formulation. Results of this study showed that all formulations had dissolutions which were in accordance with Brazilian Pharmacopoeia specifications, and quality control tests. An exception was found for the similar formulation, which had a hardness parameter that exceeded the USP standard. However, this difference was not significant given the similar formulation's satisfactory disintegration time.O objetivo desse trabalho foi avaliar a qualidade de cinco formulações de carbamazepina na dosagem de 200,00 mg: medicamento referência Tegretol® (Novartis), medicamento genérico (indústria nacional), medicamento similar (indústria nacional) e cápsulas do mesmo medicamento obtidas de duas farmácias de manipulação da cidade do Natal, RN. Os ensaios realizados foram: peso médio, diâmetro, espessura, teor, dissolução, desintegração, dureza, friabilidade e umidade. Foi observado que nenhuma das amostras analisadas apresentou friabilidade superior ao limite máximo determinado pela Farmacopéia Americana (1,5%). O medicamento genérico, apesar de apresentar dureza superior em relação ao medicamento de referência, desintegrou em menor tempo, o que pode estar relacionado à crospovidona presente na formulação. As amostras analisadas atenderam às especificações da Farmacopéia Brasileira no que diz respeito à dissolução. Em geral, os resultados das amostras A, B, C, D e E foram considerados satisfatórios uma vez que atenderam as especificações farmacopéicas. Embora a apresentação similar não tenha atendido ao padrão USP no que diz respeito à dureza, esse dado não se mostrou significativo, uma vez que o tempo de desintegração foi satisfatório.porUniversidade de São Paulo, USPCarbamazepineMedicines/quality controlGeneric medicinesSimilar medicinesMedicines/magistral formulationDetermination of carbamazepine in pharmaceutical formulationsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNTEXTDetermination of carbamazepine in pharmaceutical formulations_2010.pdf.txtDetermination of carbamazepine in pharmaceutical formulations_2010.pdf.txtExtracted texttext/plain22742https://repositorio.ufrn.br/bitstream/123456789/25361/3/Determination%20of%20carbamazepine%20in%20pharmaceutical%20formulations_2010.pdf.txt4f244859c4bfcd6eed588568e21039bfMD53THUMBNAILDetermination of carbamazepine in pharmaceutical formulations_2010.pdf.jpgDetermination of carbamazepine in pharmaceutical formulations_2010.pdf.jpgIM Thumbnailimage/jpeg7381https://repositorio.ufrn.br/bitstream/123456789/25361/4/Determination%20of%20carbamazepine%20in%20pharmaceutical%20formulations_2010.pdf.jpg155982cea03c6c0118ed2142b00fdaf8MD54ORIGINALDeterminationCarbamazepinePharmaceutical_Araujo_2010.pdfDeterminationCarbamazepinePharmaceutical_Araujo_2010.pdfapplication/pdf228529https://repositorio.ufrn.br/bitstream/123456789/25361/1/DeterminationCarbamazepinePharmaceutical_Araujo_2010.pdf73f66a9af6b667b4280bb4ec386e36aeMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.ufrn.br/bitstream/123456789/25361/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52123456789/253612021-11-11 17:23:15.281oai:https://repositorio.ufrn.br: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Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2021-11-11T20:23:15Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false
dc.title.pt_BR.fl_str_mv Determination of carbamazepine in pharmaceutical formulations
title Determination of carbamazepine in pharmaceutical formulations
spellingShingle Determination of carbamazepine in pharmaceutical formulations
Araujo, Aurigena Antunes de
Carbamazepine
Medicines/quality control
Generic medicines
Similar medicines
Medicines/magistral formulation
title_short Determination of carbamazepine in pharmaceutical formulations
title_full Determination of carbamazepine in pharmaceutical formulations
title_fullStr Determination of carbamazepine in pharmaceutical formulations
title_full_unstemmed Determination of carbamazepine in pharmaceutical formulations
title_sort Determination of carbamazepine in pharmaceutical formulations
author Araujo, Aurigena Antunes de
author_facet Araujo, Aurigena Antunes de
Solon, Lílian Grace da Silva
Oliveira, Ana Isabel Maia de
Guerra, Gerlane Coelho Bernardo
Soares, Luiz Alberto Lira
author_role author
author2 Solon, Lílian Grace da Silva
Oliveira, Ana Isabel Maia de
Guerra, Gerlane Coelho Bernardo
Soares, Luiz Alberto Lira
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Araujo, Aurigena Antunes de
Solon, Lílian Grace da Silva
Oliveira, Ana Isabel Maia de
Guerra, Gerlane Coelho Bernardo
Soares, Luiz Alberto Lira
dc.subject.por.fl_str_mv Carbamazepine
Medicines/quality control
Generic medicines
Similar medicines
Medicines/magistral formulation
topic Carbamazepine
Medicines/quality control
Generic medicines
Similar medicines
Medicines/magistral formulation
description The aim of this study was to evaluate the quality of five different solid formulations of carbamazepine. The reference formulation was Tegretol® 200.00 mg (Novartis) and the others were: generic formulation of carbamazepine 200.00 mg (National Industry), similar formulation of carbamazepine 200.00 mg (National Industry), and two formulations of carbamazepine 200.00 mg acquired from two different compounding pharmacies. The latter consisted of capsules obtained in Natal, the capital city of the Brazilian State of Rio Grande do Norte. The quality of samples was evaluated through physical and physical-chemical tests, including: weight, diameter, thickness, content, dissolution, disintegration, hardness, friability and moisture. The results of friability analysis showed that all formulations met Brazilian and United States Pharmacopeia (USP) specifications. In spite of having a higher hardness compared to the reference, the generic formulation had a lower disintegration time. This could be associated to the presence of crospovidone in its formulation. Results of this study showed that all formulations had dissolutions which were in accordance with Brazilian Pharmacopoeia specifications, and quality control tests. An exception was found for the similar formulation, which had a hardness parameter that exceeded the USP standard. However, this difference was not significant given the similar formulation's satisfactory disintegration time.
publishDate 2010
dc.date.issued.fl_str_mv 2010
dc.date.accessioned.fl_str_mv 2018-06-12T15:15:28Z
dc.date.available.fl_str_mv 2018-06-12T15:15:28Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv ARAUJO, Aurigena Antunes de; et al. Determination of carbamazepine in pharmaceutical formulations. Brazilian Journal of Pharmaceutical Sciences (Impresso), v. 46, p. 509-513, 2010. Disponível em: < http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502010000300014> Acesso em: 13 mar. 2018.
dc.identifier.uri.fl_str_mv https://repositorio.ufrn.br/jspui/handle/123456789/25361
dc.identifier.issn.none.fl_str_mv 2175-9790
dc.identifier.doi.none.fl_str_mv http://dx.doi.org/10.1590/S1984-82502010000300014
identifier_str_mv ARAUJO, Aurigena Antunes de; et al. Determination of carbamazepine in pharmaceutical formulations. Brazilian Journal of Pharmaceutical Sciences (Impresso), v. 46, p. 509-513, 2010. Disponível em: < http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502010000300014> Acesso em: 13 mar. 2018.
2175-9790
url https://repositorio.ufrn.br/jspui/handle/123456789/25361
http://dx.doi.org/10.1590/S1984-82502010000300014
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Universidade de São Paulo, USP
publisher.none.fl_str_mv Universidade de São Paulo, USP
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRN
instname:Universidade Federal do Rio Grande do Norte (UFRN)
instacron:UFRN
instname_str Universidade Federal do Rio Grande do Norte (UFRN)
instacron_str UFRN
institution UFRN
reponame_str Repositório Institucional da UFRN
collection Repositório Institucional da UFRN
bitstream.url.fl_str_mv https://repositorio.ufrn.br/bitstream/123456789/25361/3/Determination%20of%20carbamazepine%20in%20pharmaceutical%20formulations_2010.pdf.txt
https://repositorio.ufrn.br/bitstream/123456789/25361/4/Determination%20of%20carbamazepine%20in%20pharmaceutical%20formulations_2010.pdf.jpg
https://repositorio.ufrn.br/bitstream/123456789/25361/1/DeterminationCarbamazepinePharmaceutical_Araujo_2010.pdf
https://repositorio.ufrn.br/bitstream/123456789/25361/2/license.txt
bitstream.checksum.fl_str_mv 4f244859c4bfcd6eed588568e21039bf
155982cea03c6c0118ed2142b00fdaf8
73f66a9af6b667b4280bb4ec386e36ae
8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)
repository.mail.fl_str_mv
_version_ 1802117654897491968